Combination chemotherapy of 6-thioguanine with various antitumor agents against murine leukemia L-1210.
Antitumor activity of 6-thioguanine against L-1210 leukemia was studied in combination with various antitumor agents in clinical stages, such as mitomycin-C, carbazilquinone, cyclophosphamide, 3,3'-dimesyloxydipropylamine tosylate (864T), 4-hydroperoxyisophosphamide, and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chlorethyl)-1-nitrosourea hydrochloride (ACNU). The combination treatments with 6-thioguanine and each of six agents, especially with ACNU, showed a distinct therapeutic effect against the early L-1210 leukemia at dosage levels not producing any significant antitumor activity with each agent alone (ip-ip). The excellent antitumor activity of the combination of 6-thioguanine with ACNU was also proved in various sites of tumor inoculation and routes of drug administration systems, i.e., ip-iv, iv-ip, and iv-iv systems. Moreover, the effectiveness of the combination of these two drugs was clearly shown against advanced L-1210 leukemia which was refractory to each agent alone.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D007069:Ifosfamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D008698:Mesylates / Q000627:therapeutic use; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D013866:Thioguanine / Q000008:administration & dosage / Q000627:therapeutic use*; D014105:Tosyl Compounds / Q000627:therapeutic use
D000970:Antineoplastic Agents; D008698:Mesylates; D008937:Mitomycins; D009607:Nitrosourea Compounds; D014105:Tosyl Compounds; C001441:improsan; C012353:hydroperoxyisophosphamide; D003520:Cyclophosphamide; D013866:Thioguanine; D007069:Ifosfamide